Pomalidomide-PEG3-C2-NH2 (TFA) is primarily used in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker molecule, connecting a target protein ligand (such as pomalidomide) to an E3 ubiquitin ligase recruiter. This facilitates the degradation of specific disease-causing proteins, making it valuable in treating conditions like multiple myeloma and other cancers. Additionally, its PEG3 spacer enhances solubility and stability, improving its pharmacokinetic properties for therapeutic applications.